Cogentus Pharmaceuticals

The company's primary business was the development of fixed-dose combination prescription medicines designed to address significant unmet medical needs. Its main product candidate was CGT-2168, a novel oral formulation that combined the antiplatelet drug clopidogrel with a gastro-protectant, omeprazole. This single-pill combination was engineered to mitigate the gastrointestinal side effects, such as bleeding, commonly associated with dual antiplatelet therapy, a standard treatment for many cardiac patients. The goal was to offer a safer treatment alternative that maintained the full cardiovascular benefits of antiplatelet therapy while reducing potentially dangerous side effects.

Cogentus Pharmaceuticals successfully raised a total of $77.5 million in funding over two rounds. A significant financing milestone was a Series C round on December 20, 2007, which raised $62.5 million. This funding was intended to support the global Phase 3 clinical trial program for CGT-2168, known as the COGENT trials, which planned to enroll thousands of patients across the United States, Canada, Europe, and South America. Key investors included the Keffi Group, Prospect Venture Partners, Ridgeback Capital, Apothecary Capital, and Pinnacle Ventures. Despite its promising product and significant funding, the company filed for Chapter 7 liquidation on January 16, 2009, and is now considered deadpooled.